Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1802results about How to "Inhibit expression" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Transgenic non-human animals for producing chimeric antibodies
InactiveUS20060015957A1Inhibit expressionEasy to switchImmunoglobulinsGenetic engineeringAntigenHuman animal
The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.
Owner:GENPHARM INT INC
Methods for genetic control of insect infestations in plants and compositions thereof
ActiveUS20070124836A1Inhibit expressionReduced expression levelSugar derivativesClimate change adaptationBiotechnologyDouble strand
The present invention relates to control of pest infestation by inhibiting one or more biological functions. The invention provides methods and compositions for such control. By feeding one or more recombinant double stranded RNA molecules provided by the invention to the pest, a reduction in pest infestation is obtained through suppression of gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, and to particular combinations of transgenic pesticidal agents for use in protecting plants from pest infestation.
Owner:MONSANTO TECH LLC
Nucleic acid molecules that target the vacuolar atpase h subunit and confer resistance to coleopteran pests
InactiveUS20120198586A1Providing coleopteran pest resistanceInhibit expressionBiocideFungiGMO PlantsNucleic acid molecule
This disclosure concerns nucleic acid molecules and methods of use thereof for control of coleopteran pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in coleopteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of coleopteran pests, and the plant cells and plants obtained thereby.
Owner:DOW AGROSCIENCES LLC
MicroRna-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers
ActiveUS20080306006A1Inhibiting tumorigenesisPrevent proliferationOrganic active ingredientsPeptide/protein ingredientsMicroRNASolid cancer
The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provide methods of identifying inhibitors of tumorigenesis.
Owner:THE OHIO STATE UNIV RES FOUND
Oligonucleotide analogs having cationic intersubunit linkages
ActiveUS7943762B2High expressionHigh activitySugar derivativesActivity regulationNeutral Amino AcidsOligomer
Owner:AVI BIOPHARMA
Identification and use of target genes for control of plant parasitic nematodes
ActiveUS20070250947A1Raise the possibilityLevel confidenceBiocideOrganic active ingredientsNematodePlant cell
The invention relates to identifying and evaluating target coding sequences for control of plant parasitic nematodes by inhibiting one or more biological functions, and their use. The invention provides methods and compositions for identification of such sequences and for the control of a plant-parasitic nematode population. By feeding one or more recombinant double stranded RNA molecules provided by the invention to the nematode, a reduction in disease may be obtained through suppression of nematode gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, and the plant cells and plants obtained thereby.
Owner:MONSANTO TECH LLC
Method and apparatus for device controlled gene expression
InactiveUS20050192637A1Readily be titratedPreventing and inhibiting and cardiac conditionGenetic material ingredientsHeart defibrillatorsForms of energyRegulator gene
A gene regulatory system controls gene therapy by emitting one or more forms of energy that regulate gene expression by triggering promoters. The system includes a sensor to sense a signal indicative of a need for the gene therapy as well as responses to the gene therapy. The regulation of the gene expression is controlled based on the sensed signal and / or a user command. In one embodiment, the system delivers one or more electrical therapies in conjunction with the gene therapy.
Owner:CARDIAC PACEMAKERS INC
Antisense modulation of bcl-x expression
InactiveUS7148204B2Promote apoptosisReduce expressionBiocideHeavy metal active ingredientsDiseaseSensitized cell
Compositions and methods are provided for modulating the expression of bcl-x. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bcl-x are preferred. Methods of using these compounds for modulation of bcl-x expression and for treatment of diseases associated with expression of bcl-x are also provided. Methods of sensitizing cells to apoptotic stimuli are also provided.
Owner:IONIS PHARMA INC
Oligonucleotide analogs having cationic intersubunit linkages
ActiveUS20090088562A1Avoid infectionReduce viral infectionSugar derivativesActivity regulationNeutral Amino AcidsOligomer
Morpholino oligomers containing both uncharged and cationic intersubunit linkages are provided. The oligomers are oligonucleotide analogs containing predetermined sequences of base-pairing moieties. The presence of the cationic intersubunit linkages in the oligomers, typically at a level of about 10-50% of total linkages, provides enhanced antisense activity, in various antisense applications, relative to the corresponding uncharged oligomers. Also provided are such oligomers conjugated to peptide transporter moieties, where the transporters are preferably composed of arginine subunits, or arginine dimers, alternating with neutral amino acid subunits.
Owner:AVI BIOPHARMA
Prevention of regression in thermal ciliary muscle tendinoplasty
InactiveUS7044945B2Reduce the amplitudeReduce rangeLaser surgeryDiagnosticsCollagen shrinkageCross-link
Methods and apparatus are provided that prevent or inhibit functional regression caused by the stromal remodeling resulting from epithelial or fibroblastic apoptosis or necrosis in patients who will undergo or have undergone a thermal ciliary muscle tendinoplasty or scleral collagen shrinkage procedures. Methods and compositions are provided that prevent apoptosis in epithelial cells by stromal cooling during thermal tendinoplasty procedures; that create or restore stabilizing molecular cross-links between scleral stromal lamellar fibers; and that interrupt at least one step in the stromal remodeling response including inhibition of apoptosis, fibroblastic proliferation and migration, and inhibition of collagenesis.
Owner:SAND BRUCE J
Transgenic non-human animals for producing heterologous and chimeric antibodies
The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.
Owner:GENPHARM INT INC
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
InactiveUS7235653B2Inhibition of activationPrevent proliferationBiocideSugar derivativesProtein compositionOligonucleotide
Compositions and methods for the treatment of asthma with oligonucleotides which specifically hybridize with nucleic acids encoding B7 proteins.
Owner:IONIS PHARMA INC
Nucleic Acid Complex
The present invention relates to modification of nucleic acids for specific delivery in vitro and in vivo. More specifically, the present invention relates to modification of RNA or DNA molecules in order to add functions in terms of delivery and specificity to RNA interference or antisense technology. A specific binding domain is incorporated into the nucleic acid to which a complementary nucleic acid, conjugated to a biologically active molecule, can hybridize.
Owner:AVARIS
MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
ActiveUS20080261908A1Prevent proliferationInhibit expressionOrganic active ingredientsMicrobiological testing/measurementOncologyAnti breast cancer
The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of breast cancer. The invention also provides methods of identifying anti-breast cancer agents.
Owner:THE OHIO STATE UNIV RES FOUND
Expression profile of prostate cancer
InactiveUS7229774B2Reduce proliferationInhibit expressionMicrobiological testing/measurementDepsipeptidesCancer drugsProstate cancer
Owner:RGT UNIV OF MICHIGAN
High affinity human antibodies and human antibodies against human antigens
The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention also is directed to methods for producing human sequence antibodies.
Owner:GENPHARM INT INC
Human application of engineered chimeric antigen receptor (CAR) T-cells
ActiveUS9629877B2Promote proliferation and survivalInhibit expressionImmunoglobulins against cell receptors/antigens/surface-determinantsMammal material medical ingredientsHuman bodyElectroporation
The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Substituted Phenols as Active Agents Inhibiting Vegf Production
The present invention relates to methods, compounds, and compositions for inhibiting angiogenesis. More particularly, the present invention relates to methods, compounds, and compositions for inhibiting VEGF production.
Owner:PTC THERAPEUTICS INC
Methods for the treatment, diagnosis, and prognosis of cancer
InactiveUS20060160762A1Reduce the overall heightImprove the level ofPeptide/protein ingredientsGenetic material ingredientsCancer cellCancer treatment
We have discovered that antizyme inhibitor (AZI) is expressed at increased levels in highly proliferating cells. We have also discovered that inhibiting antizyme inhibitor, including inhibiting its expression, reduces the growth of cancer cells. The present invention is directed to the use of inhibitors of antizyme inhibitor for the treatment of cancer, the use of antizyme inhibitor for the diagnosis and prognosis of cancer, and methods for identifying novel cancer treatments.
Owner:CHILDRENS MEDICAL CENT CORP
Interleukin-1 receptor antagonists, compositions, and methods of treatment
ActiveUS20060094663A1Synthetic is simpleInhibition of activationNervous disorderPeptide/protein ingredientsArthritisDrug biological activity
Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R / IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease as well as other chronic or acute inflammatory diseases. This invention also discloses an isolated compound having an IL-1R antagonist activity, said compound being selected from the group consisting of: a peptide comprising the amino acid sequence RYTPELX, wherein R, Y, T, P, E, L, refer to their corresponding amino acids, and X is selected from no amino acid and alanine (A); and a derivative of (a) wherein the derivative incorporates one, two or three amino acid modification selected from an amino acid addition, deletion or substitution in the RYTPEL portion of the peptide, and wherein said derivative maintains its antagonist IL-1R activity.
Owner:VALORISATION HSJ LLP
Methods and sequences to suppress primate huntington gene expression
InactiveUS20060257912A1Inhibit expressionLower Level RequirementsGenetic material ingredientsFermentationPrimateGene
Disclosed herein are sequences, molecules and methods used to suppress the expression of HD genes encoding for huntingtin protein in primates including Macaca mulatta and Homo sapiens. These sequences, molecules and methods aid in the study of the pathogenesis of HD and can also provide a treatment for this disease.
Owner:MEDTRONIC INC
Meganuclease variants cleaving a DNA target sequence from the rhodopsin gene and uses thereof
InactiveUS20130183282A1Recovery functionInhibit expressionFusion with DNA-binding domainSugar derivativesA-DNANuclease
The invention relates to meganuclease variants which cleave a DNA target sequence from the human Rhodopsin gene (RHO), to vectors encoding such variants, to a cell, an animal or a plant modified by such vectors and to the use of these meganuclease variants and products derived therefrom for genome therapy, ex vivo (gene cell therapy) and genome engineering including therapeutic applications and cell line engineering.
Owner:CELLECTIS SA
Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system
InactiveUS20100215588A1Suppress gene expressionInhibit expressionSpecial deliveryAerosol deliveryDiseaseIntensive care medicine
The present invention relates to methods of treating respiratory disorders of all types, including pulmonary disorders, by delivering inhibitory nucleic acid molecules directly to the respiratory system. siRNAs or other nucleic acids are delivered to the lung / respiratory system for the treatment of disease.
Owner:QUARK FARMACUITIKALS INC
Reagents, methods and systems to suppress pro-inflammatory cytokines
ActiveUS20080124370A1Inhibit inflammationInhibit expressionAntipyreticGenetic material ingredientsMedicineCytokine
The present invention relates to reagents, methods and systems to treat inflammation and pain in a subject using small interfering RNA (siRNA) molecules targeted to either TNFα, IL1, IL6 and other pro-inflammatory cytokines.
Owner:WARSAW ORTHOPEDIC INC
Compositions and methods for inhibiting expression of factor vii gene
ActiveUS20090264511A1Decrease in levelLower protein levelOrganic active ingredientsAntipyreticDouble strandFactor VII
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor VII gene.
Owner:ALNYLAM PHARMA INC
Methods for Controlling Pests Using Rnai
InactiveUS20090306189A1Growth inhibitionInhibit expressionAntibacterial agentsBiocidePest infestationDouble stranded rna
The present invention relates to methods for controlling pest infestation using double stranded RNA molecules. The invention provides methods for producing transgenic cells expressing the double stranded RNA molecules, as well as compositions and commodity products containing or treated with such molecules.
Owner:DEVGEN NV
Nucleic acid molecules that confer resistance to coleopteran pests
ActiveUS20120174258A1Providing coleopteran pest resistanceInhibit expressionBiocidePeptidesGMO PlantsNucleic acid molecule
This disclosure concerns nucleic acid molecules and methods of use thereof for control of coleopteran pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in coleopteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of coleopteran pests, and the plant cells and plants obtained thereby.
Owner:DOW AGROSCIENCES LLC
Compositions and methods for silencing aldehyde dehydrogenase
InactiveUS8999950B2Increasing the amount of acetaldehydeIntensifying the adverse effectsOrganic active ingredientsNervous disorderAlcoholismsLipid formation
The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target aldehyde dehydrogenase (ALDH) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and / or administering the lipid particles (e.g., for treating alcoholism in humans).
Owner:PROTIVA BIOTHERAPEUTICS
Novel siRNAS and methods of use thereof
InactiveUS20090162365A1Effective treatmentInhibit expressionSenses disorderNervous disorderDiseaseMedicine
The invention relates to compounds, in particular siRNAs, which inhibit the expression of specific human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The present invention also provides a method of treating and / or preventing the incidence or severity of various diseases or conditions associated with the genes and / or symptoms associated with such diseases or conditions comprising administering to a subject in need of treatment for such disease or condition and / or symptom the compound or the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject. The invention also provides antibodies which inhibit specified human polypeptides and pharmaceutical compositions comprising one or more such antibodies.
Owner:QUARK FARMACUITIKALS INC
Methods for genetic control of plant pest infestation and compositions thereof
ActiveUS20090188005A1Inhibit expressionEffectively suppressing a target sequenceSugar derivativesClimate change adaptationPlant nematodeDouble strand
The present invention is directed to controlling plant pest infestation, and particularly plant nematode infestation, by inhibiting one or more biological functions in the plant pest. The invention discloses methods and compositions for use in controlling plant pest infestation by providing one or more different recombinant double stranded RNA molecules in the diet of the pest in order to achieve a reduction in pest infestation through suppression of pest gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, to methods for detecting cells comprising the disclosed sequences, and to methods for detecting the disclosed sequences in biological samples.
Owner:MONSANTO TECH LLC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com